• Home
  • News
  • Weightlifting Athlete Lawrence Letellier Accepts Sanction for Anti-Doping Rule Violation

Weightlifting Athlete Lawrence Letellier Accepts Sanction for Anti-Doping Rule Violation

USADA

Press Release

5th December 2019

USADA announced today that Lawrence Letellier, of San Angelo, Texas, an athlete in the sport of weightlifting, has accepted a two-year suspension for an anti-doping rule violation.

Letellier, 34, tested positive for clomiphene as the result of an in-competition drug test conducted at the American Open Series 2 on July 27,2019.

Clomiphene is a Specified Substance in the class of Hormone and Metabolic Modulators and is prohibited at all times under the USADA Protocol for Olympic and Paralympic Movement Testing, the United States Olympic and Paralympic Committee National Anti-Doping Policies, and the International Weightlifting Federation Anti-Doping Policy, all of which have adopted the World Anti-Doping Code and the World Anti-Doping Agency Prohibited List.

Letellier’s two-year period of ineligibility began on July 27, 2019, the date his positive sample was collected. In addition, Letellier has been disqualified from competitive results obtained on and subsequent to July 27, 2019, including forfeiture of any medals, points and prizes.

 

Leave a comment

Please login to leave a comment.

Courses

Legal Advisors

Upcoming Events

There are no up-coming events

Copyright © LawInSport Limited 2010 - 2021. These pages contain general information only. Nothing in these pages constitutes legal advice. You should consult a suitably qualified lawyer on any specific legal problem or matter. The information provided here was accurate as of the day it was posted; however, the law may have changed since that date. This information is not intended to be, and should not be used as, a substitute for taking legal advice in any specific situation. LawInSport is not responsible for any actions taken or not taken on the basis of this information. Please refer to the full terms and conditions on our website.